Iovance Biotherapeutics

Historical price data

Iovance Biotherapeutics' mission is to be the global leader in developing and delivering TIL therapy for cancer. Its landmark achievement is the FDA accelerated approval of Amtagvi™ (lifileucel) in February 2024, the first-ever approved TIL therapy, validating its core platform. The company's strategy is to commercialize Amtagvi in melanoma, expand its label into earlier lines of therapy and new tumor types, and advance next-generation genetically modified TIL therapies through its integrated manufacturing facility, the Iovance Cell Therapy Center (iCTC).

Proprietary tumor-infiltrating lymphocyte (TIL) platform that harvests, expands, and reinfuses a patient's own polyclonal T-cells to target diverse neoantigens in solid tumors, supported by a streamlined 22-day manufacturing process.